Thursday, May 2, 2013
This week in therapeutics
Publication and contact
SEC24 family member A (SEC24A); proprotein
convertase subtilisin/kexin type 9 (PCSK9);
lipoprotein receptor (LDLR)
Mouse studies suggest
inhibiting SEC24A could help treat hypercholesterolemia and related metabolic
indications. In mice, a Sec24a deficiency decreased hepatic secretion of Pcsk9
and increased Ldlr expression compared with no Sec24a deficiency. In the
Sec24a-deficient mice, circulating levels of high-density lipoprotein,
low-density lipoprotein and total cholesterol were lower than those in
nondeficient controls. Next steps include testing the effects of SEC24A
knockdown in human hepatocytes.
AMG 145, a human mAb against
PCSK9 from Amgen
Inc., is in Phase III testing to treat
hypercholesterolemia, hyperlipidemia and dyslipidemia.
a human mAb targeting PCSK9 from Regeneron
Pharmaceuticals Inc. and Sanofi,
is in Phase III testing to treat hypercholesterolemia.
a PCSK9 inhibitor from Pfizer
Inc., is in Phase II testing to treat hypercholesterolemia
and acute coronary syndrome.
Published online May 2, 2013
Unpatented; available for
partnering or licensing from the University
Contact: Robin Rasor, University of
Michigan, Ann Arbor, Mich.
Chen, X.-W. et al. eLife;
published online April 9, 2013;
Contact: David Ginsburg, University of Michigan, Ann Arbor,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]